Endovascular Robotics Market (2026-2036)

The growth of this market is mainly driven by occupational radiation and orthopedic hazards facing interventional physicians, rising volumes of endovascular procedures driven by vascular disease and stroke, and new technologies and commercial models, including single-use robots that remove capital barriers. However, past commercial setbacks and limited adoption, high costs and the lack of dedicated reimbursement, limited device compatibility and haptic feedback, and regulatory hurdles for new indications restrain the growth of this market.

Furthermore, remote and telerobotic stroke intervention, peripheral procedures in ambulatory and office-based settings, and robotic electrophysiology and structural heart procedures are expected to offer growth opportunities for the stakeholders in this market. However, demonstrating patient outcome benefits beyond radiation reduction, integrating robots into catheterization laboratory workflows, ensuring network reliability for telerobotic intervention, and competition from radiation protection alternatives remain major challenges impacting the growth of this market. Additionally, the shift to single-use robotic systems, AI-assisted and autonomous navigation, telerobotic intervention, and magnetic navigation and microrobotics are prominent trends in this market.

The Endovascular Robotics Market comprises robotic systems that manipulate catheters, guidewires, balloons, stents, and other devices inside blood vessels and the heart, allowing interventional physicians to perform procedures from a shielded console away from the X-ray source. The market covers electromechanical systems that drive standard catheters and guidewires, magnetic navigation systems that steer magnetically tipped catheters using external magnetic fields, robotic steerable catheters, and emerging AI-guided and autonomous navigation systems, together with single-use robotic devices, disposable cassettes, software, and services. Applications include peripheral vascular interventions, coronary interventions, neurovascular procedures such as stroke thrombectomy and aneurysm treatment, cardiac electrophysiology, structural heart interventions, and interventional oncology procedures such as embolization. General surgical robots, robotic bronchoscopy, and imaging systems sold separately are excluded. The ecosystem spans robotics developers, catheter and guidewire manufacturers, imaging companies, hospitals and catheterization laboratories, ambulatory surgery centers and office-based labs, physician societies, regulators, and payers.

The market is being reshaped by new entrants and business models after earlier setbacks. Siemens Healthineers ended sales of the Corindus CorPath GRX system for vascular procedures in 2023, several years after acquiring Corindus, and Hansen Medical's Magellan robotic catheter system did not achieve broad adoption before the company was acquired by Auris Health in 2016. On 8 September 2025, the U.S. FDA cleared Microbot Medical's LIBERTY Endovascular Robotic System, the first single-use, remotely operated robotic system for peripheral endovascular procedures, designed to avoid the capital equipment and dedicated infrastructure required by earlier robots. Its pivotal study showed 100% success in robotic navigation to target, zero device-related adverse events, and a 92% relative reduction in physician radiation exposure, and the company began a limited market release in November 2025 and planned full market release at the Society of Interventional Radiology conference in April 2026.

Occupational hazards are a central driver. Interventional cardiologists, radiologists, and neurointerventionalists spend long hours near X-ray sources wearing heavy lead aprons, and studies have linked this work to orthopedic injuries and have raised concerns about radiation-associated conditions, including a 2013 case series of 31 interventional physicians with brain tumors, 85% of which were on the left side of the head, the side typically closer to the X-ray source. Rising procedure volumes are adding to demand: Microbot Medical estimates approximately 2.5 million peripheral endovascular procedures are performed in the U.S. each year, peripheral artery disease affects more than 200 million people worldwide, and stroke, which requires rapid access to thrombectomy, affects about 12 million people each year according to the World Stroke Organization.

Other developers are expanding the field. Stereotaxis markets magnetic navigation systems widely used in cardiac electrophysiology, France's Robocath developed the R-One robotic platform for coronary procedures and partnered with MicroPort to address China, and startups including Nanoflex Robotics, XCath, and Sentante are developing systems for neurovascular and remote interventions. Telerobotic intervention, first demonstrated in a remote coronary stent procedure performed from about 20 miles away in 2018, could extend expert care, particularly for stroke, to hospitals without specialists.